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Between 1935 and the mid-fifties, the fatality rate from
acute bacterial meningitis decreased impressively from
85% to 37% [1]. This striking reduction was clearly due
to the introduction of antimicrobial agents [1]. However,
between the sixties and the mid-nineties, the prognosis
did not substantially improve and the mortality rate re-
mained roughly stable at 20–25% [1, 2, 3, 4, 5, 6, 7]. It is
unclear why there was no further improvement of the
prognosis during three decades, despite new and more
potent antibiotics such as third generation cephalospor-
ins (cetriaxone, cefotaxime) and despite broader avail-
ability of, and more sophisticated, critical care medicine.
During the past two decades, important progress has
been made in understanding the pathogenesis of meningitis
[8, 9, 10]. The mechanisms of neuro-invasion and inflam-
mation have been elucidated. The pathogenesis of cortical
necrosis on the one hand and hippocampal apoptosis on the
other have been studied. It has been shown that oxidative
radicals play a crucial and noxious role for cerebral blood
flow and consecutive cortical brain damage. In addition,
the complex effects of nitric oxide have been analyzed. In-
terestingly, depending on the stage of bacterial meningitis,
inhibition of nitric oxide synthase can either diminish or
aggravate cerebral blood flow and consecutively result in
brain damage [8 for review]. Since hippocampal apoptosis
leads to neurologic sequelae or even death, the underlying
mechanisms of apoptosis have been studied. In brief, inhi-
bition of matrix metalloproteinases and TNF-alpha con-
verting enzyme was experimentally beneficial, whereas
corticosteroids and radical oxygen scavengers even aggra-
vated apoptosis [11, 12]. In view of these complex effects,
even in the well defined setting of experimental pneumo-
coccal meningitis, it is not astonishing that these experi-
mental data have not yet translated into improved outcome
of meningitis in humans.
Table 1 summarizes the fatality rates of patients with
meningitis during various successive time periods from
Table 1 Fatality rates of bacterial meningitis during the last 40 years
Time period Overall (%) Due to Streptococcus pneumoniae (%) Author
1962–88 25 28.5 Durand et al. [2]
1970–95 27 Not reported Aronin et al. [3]
1978–81 13.2 26.3 Schlech et al. [4]
1975–94 19.7 25.9 Sigurdardottir et al. [5]
1985–96 18 26 Hussein et al. [6]
1994–95 13.3 21 Schuchat et al. [7]
1993–01 Control 15 34 De Gans et al. [13]
Dexamethasone 7 14
1995–00 10.9 <16* Flores-Cordero et al. [14]
*16% unfavorable outcome (neurologic sequelae and death)
1869
1962–2001. Whereas the overall mortality varied by up
to 50% (13.2–27.0%) between 1962–1995, regardless of
the study period, mortality due to pneumococcal menin-
gitis remained quite stable, ranging between 21% and
28% during the three decades. Thus, novel antibiotics,
knowledge in pathogenesis and better supportive care
did not translate into measurably better outcome. It is
conceivable that improvements over time in the man-
agement of meningitis are not visible in terms of an
overall fatality rate, due to the selective decrease of
those types of meningitis with good prognosis. The case
fatality rate of meningitis due to Haemophilus influen-
zae and Neisseria meningitidis is low, namely 6% and
3%, respectively, whereas mortality due to pneumococ-
cal and listerial meningitis is 21% and 15%, respective-
ly [7]. Since vaccination against Haemophilus influen-
zae and Neisseria meningitidis is widely used nowa-
days, these etiologies have become rare. In contrast, the
prevalence of etiologies associated with higher fatality
rates (Streptococcus pneumoniae, S. aureus, Listeria
monocytogenes) have not decreased. In addition, in-
creasing resistance to beta-lactams of strains causing
pneumococcal meningitis may counteract the improve-
ment of supportive care. Thus, decreasing the overall fa-
tality rate of meningitis now requires either an effica-
cious prophylaxis against high-risk meningitis (e.g. con-
jugated pneumococcal vaccine against a broad spectrum
of capsular types) or better management of pneumococ-
cal meningitis.
The prospective, randomized, double-blind trial of ad-
juvant therapy with dexamethasone in adults with bacte-
rial meningitis shows that there is room for improved
management (Table 1) [13]. Patients who profit from
dexamethasone (10 mg every 6 h over 4 days, starting
before or at the time of antibiotic therapy) are those with
pneumococcal meningitis and with a Glasgow Coma
Scale (GCS) score between 8–11. In this issue of Inten-
sive Care Medicine, Flores-Cordero et al. [14] report
their data of a prospective observational study of adult
patients with acute community-acquired bacterial menin-
gitis. They report an impressively low overall fatality
rate of 10.9%. Their rate of meningitis without identified
pathogen was quite high (26.5%), probably due to the
frequent use of antibiotics before microbiological sam-
pling (29.6%). However, even the rate of unfavorable
outcome (neurologic sequelae and death) of patients with
pneumococcal meningitis was very low, at 16%, despite
the fact that 12% of the isolates were non-susceptible to
cefotaxime.
In their study, significant risk factors for adverse out-
come were age over 50 years, neurologic abnormalities
at admission, as well as a GCS of 10 or less and an
APACHE II score higher than 13. Therefore, the good
prognosis reported by Flores-Cordero et al. [14] was
probably due to three factors: (1) low median age
(46 years compared to 57 years in the study of Aronin et
al. [3], (2) low initial APACHE II score of 11.5 and (3)
relatively high initial GCS of 11. Whereas the good ini-
tial clinical status was obviously due to a very high de-
gree of suspicion by the general practitioner and the
emergency room physician, the potential role of other
factors cannot be answered with the data of this study.
However, it is possible that rapid antimicrobial therapy
was crucial, as suggested by Aronin et al. [3]. Unfortu-
nately, the role of steroids and of supportive care in the
intensive care unit cannot be estimated from this study,
since the protocol did not control for these factors.
Despite the fact that the fatality rate of bacterial men-
ingitis is finally decreasing, there is still need for im-
provement. Rapid hospitalization in cases of clinical sus-
picion of meningitis, microbiological sampling without
delay, rapid treatment of selected patients with steroids,
initiation of antimicrobial therapy as soon as possible
and ICU hospitalization of patients with high APACHE
II score or low GCS should be standard care. Whether
further knowledge about the pathogenesis will result in
successful adjuvant treatment modalities remains to be
proven in clinical studies.
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